MX368373B - Analogos de cortistatina para el tratamiento de enfermedades con componente inflamatorio y/o inmune. - Google Patents
Analogos de cortistatina para el tratamiento de enfermedades con componente inflamatorio y/o inmune.Info
- Publication number
- MX368373B MX368373B MX2016003490A MX2016003490A MX368373B MX 368373 B MX368373 B MX 368373B MX 2016003490 A MX2016003490 A MX 2016003490A MX 2016003490 A MX2016003490 A MX 2016003490A MX 368373 B MX368373 B MX 368373B
- Authority
- MX
- Mexico
- Prior art keywords
- rti
- inflammatory
- treatment
- immune diseases
- analogues
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
- 208000026278 immune system disease Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- DDRPLNQJNRBRNY-WYYADCIBSA-N cortistatin-14 Chemical class C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1)NC(=O)[C@H]1NCCC1)C(=O)N[C@@H](CCCCN)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 DDRPLNQJNRBRNY-WYYADCIBSA-N 0.000 abstract 3
- 102100030851 Cortistatin Human genes 0.000 abstract 2
- 229930185483 Cortistatin Natural products 0.000 abstract 2
- 108010005430 cortistatin Proteins 0.000 abstract 2
- 101800001586 Ghrelin Proteins 0.000 abstract 1
- 102000012004 Ghrelin Human genes 0.000 abstract 1
- 102000000393 Ghrelin Receptors Human genes 0.000 abstract 1
- 108010016122 Ghrelin Receptors Proteins 0.000 abstract 1
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 108010056088 Somatostatin Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 1
- 229960000553 somatostatin Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C07K14/6555—Somatostatins at least 1 amino acid in D-form
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Birds (AREA)
Abstract
La presente invención se refiere a compuestos análogos de cortistatina y sus usos. Los compuestos de la invención son ligandos peptídicos con potencial aplicación en el diagnóstico, prevención o terapia de aquellas patologías donde se encuentran expresados receptores susceptibles de unión con corlistatina, específicos o compartidos con otras moléculas como somatostatina y/o grhelina (GHSR), y que además tengan una mayor estabilidad en suero que la cortistatina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382361 | 2013-09-18 | ||
| PCT/EP2014/069842 WO2015040089A1 (en) | 2013-09-18 | 2014-09-17 | Co rti statin analogues for the treatment of inflammatory and/or immune diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016003490A MX2016003490A (es) | 2016-07-06 |
| MX368373B true MX368373B (es) | 2019-09-27 |
Family
ID=49880656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016003490A MX368373B (es) | 2013-09-18 | 2014-09-17 | Analogos de cortistatina para el tratamiento de enfermedades con componente inflamatorio y/o inmune. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20160185822A1 (es) |
| EP (1) | EP3046933B1 (es) |
| JP (1) | JP6989260B2 (es) |
| KR (1) | KR102285939B1 (es) |
| CN (1) | CN105579467B (es) |
| AU (1) | AU2014323131B2 (es) |
| BR (1) | BR112016005731B1 (es) |
| CA (1) | CA2921324C (es) |
| CL (1) | CL2016000392A1 (es) |
| DK (1) | DK3046933T3 (es) |
| ES (1) | ES2728319T3 (es) |
| HK (1) | HK1218122A1 (es) |
| HU (1) | HUE043206T2 (es) |
| IL (1) | IL244317B (es) |
| LT (1) | LT3046933T (es) |
| MX (1) | MX368373B (es) |
| MY (1) | MY185593A (es) |
| NZ (1) | NZ717035A (es) |
| PL (1) | PL3046933T3 (es) |
| PT (1) | PT3046933T (es) |
| RU (1) | RU2678315C2 (es) |
| SG (1) | SG11201601036UA (es) |
| UA (1) | UA119148C2 (es) |
| WO (1) | WO2015040089A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016014760A2 (pt) | 2013-12-24 | 2017-12-12 | Harvard College | composto, composição farmacêutica, métodos para tratamento de uma condição, para inibir e validar atividade de cinase, para modular o trajeto de b-catenina e o trajeto de tgfb/bmp em uma célula, para modular a atividade de stat1 e de hif-1-alfa em uma célula, para aumentar a expressão de bim e para preparar um composto, mutante, e, proteína |
| EP3294298A4 (en) | 2015-05-08 | 2018-10-17 | President and Fellows of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
| WO2017004411A1 (en) * | 2015-07-01 | 2017-01-05 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| JP2020526515A (ja) * | 2017-07-05 | 2020-08-31 | ウィスコンシン・アルムナイ・リサーチ・ファウンデーションＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | 遺伝子送達成果を改善する核酸と抗炎症性分子の共送達のためのミネラルコーティングされたマイクロ粒子 |
| CA3089108A1 (en) * | 2018-01-31 | 2019-08-08 | Twi Pharmaceuticals, Inc. | Topical formulations comprising tofacitinib |
| CN111936508A (zh) | 2018-03-29 | 2020-11-13 | 横向知识产权私人有限公司 | 环肽及其用途 |
| RU2698451C1 (ru) * | 2018-07-02 | 2019-08-27 | Павел Александрович Храмов | Средство и способ для лечения нейросенсорной тугоухости |
| ES2780274A1 (es) * | 2019-02-15 | 2020-08-24 | Consejo Superior De Investig Científicas (Csic) | Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente |
| JP2023504533A (ja) * | 2019-12-05 | 2023-02-03 | ベセエネ ペプチドス エセ．ア． | 癌および／または転移の治療のためのペプチド |
| CN111297876B (zh) * | 2020-01-16 | 2021-04-27 | 武汉理工大学 | 一种塞来昔布胶束和和厚朴酚胶束药物联用控释系统及其制备方法 |
| CN113797314B (zh) * | 2021-09-29 | 2023-08-22 | 山东大学齐鲁医院 | Cst多肽在制备股骨头坏死治疗药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| EP1040837A3 (en) | 1999-02-26 | 2002-01-02 | Erasmus Universiteit Rotterdam | Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder |
| TWI406671B (zh) | 2006-01-05 | 2013-09-01 | Univ Utah Res Found | 改善以神經系統為標的之藥劑之性質之方法及組合物 |
| WO2007082980A1 (es) * | 2006-01-23 | 2007-07-26 | Consejo Superior De Investigaciones Científicas | Composiciones y procedimientos para tratar trastornos inflamatorios e inmunitarios con cortistatina |
| WO2009043523A2 (en) | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Cortistatin 17 and neuropeptide 1 for use as therapeutic agent |
| EP2168983A1 (fr) * | 2008-09-30 | 2010-03-31 | Ipsen Pharma | Nouveaux composés octapeptidiques et leur utilisation thérapeutique |
| ES2351569B8 (es) | 2009-05-07 | 2012-06-20 | Bcn Peptides S.A. | Ligandos peptídicos de receptores de somatostatina. |
-
2014
- 2014-09-17 BR BR112016005731-7A patent/BR112016005731B1/pt active IP Right Grant
- 2014-09-17 LT LTEP14766508.7T patent/LT3046933T/lt unknown
- 2014-09-17 RU RU2016109410A patent/RU2678315C2/ru active
- 2014-09-17 SG SG11201601036UA patent/SG11201601036UA/en unknown
- 2014-09-17 CN CN201480048751.9A patent/CN105579467B/zh active Active
- 2014-09-17 WO PCT/EP2014/069842 patent/WO2015040089A1/en active Application Filing
- 2014-09-17 HU HUE14766508A patent/HUE043206T2/hu unknown
- 2014-09-17 US US14/912,343 patent/US20160185822A1/en active Pending
- 2014-09-17 CA CA2921324A patent/CA2921324C/en active Active
- 2014-09-17 MX MX2016003490A patent/MX368373B/es active IP Right Grant
- 2014-09-17 KR KR1020167008345A patent/KR102285939B1/ko active IP Right Grant
- 2014-09-17 EP EP14766508.7A patent/EP3046933B1/en active Active
- 2014-09-17 NZ NZ71703514A patent/NZ717035A/en unknown
- 2014-09-17 PL PL14766508T patent/PL3046933T3/pl unknown
- 2014-09-17 AU AU2014323131A patent/AU2014323131B2/en active Active
- 2014-09-17 PT PT14766508T patent/PT3046933T/pt unknown
- 2014-09-17 MY MYPI2016000336A patent/MY185593A/en unknown
- 2014-09-17 JP JP2016543392A patent/JP6989260B2/ja active Active
- 2014-09-17 ES ES14766508T patent/ES2728319T3/es active Active
- 2014-09-17 UA UAA201601741A patent/UA119148C2/uk unknown
- 2014-09-17 DK DK14766508.7T patent/DK3046933T3/da active
-
2016
- 2016-02-22 CL CL2016000392A patent/CL2016000392A1/es unknown
- 2016-02-28 IL IL244317A patent/IL244317B/en active IP Right Grant
- 2016-05-26 HK HK16106035.6A patent/HK1218122A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016003490A (es) | Analogos de cortistatina para el tratamiento de enfermedades con componente inflamatorio y/o inmune. | |
| PH12018500950A1 (en) | Subcutaneous formulations of anti-cd38 antibodies and their uses | |
| PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
| MX2015017045A (es) | Inhibidores de bromodominio biciclicos novedosos. | |
| PH12017500864A1 (en) | Anti-notch1 antibodies | |
| MX2017004838A (es) | Composiciones de interleucina-15 y usos de estas. | |
| WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
| MX2016001236A (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
| EA201201000A1 (ru) | Способы лечения колоректального рака | |
| PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
| IN2014DN08721A (es) | ||
| MX2017003211A (es) | Anticuerpos anti-met y composiciones. | |
| MX346500B (es) | Metodos y composiciones para inmunoterapia para enfermedad neural. | |
| PH12015502829A1 (en) | Lectin-like oxidized ldl receptor1 antibodies and methods of use | |
| MX2015017853A (es) | Anticuerpos contra el receptor 1 de ldl oxidada tipo lectina de metodos de uso. | |
| MX2015011518A (es) | Agentes de enlace de met y usos de los mismos. | |
| MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
| WO2013072901A3 (en) | Compositions and methods for treating glioma | |
| IN2014DN09717A (es) | ||
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| WO2014147503A3 (en) | Anti-bag3 antibodies for therapeutic use | |
| MX2015002279A (es) | Peptido pntx(19) sintético, composición farmacéutica.y uso. | |
| PH12015500822A1 (en) | Treatment of hyperproliferative and pre-cancerous skin diseases using an inhibitor of cbp/catenin | |
| MA40363A (fr) | Agents de liaison de rspo1 et leurs utilisations | |
| EA201301341A1 (ru) | Фармацевтическая композиция, обладающая панкреопротекторным действием, её применение для профилактики или лечения панкреатита и способ профилактики и лечения панкреатита |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |